Keynote 5901/30/2024 ResultsĪt data cutoff, 749 pts (83% male, 73% ESCC) were randomized (373 pembro + chemo 376 chemo). Data cutoff for interim OS/final PFS analysis was July 2, 2020. The secondary end point was ORR (RECIST v1.1 by investigator) in all pts. Primary end points were OS in pts with ESCC PD-L1 combined positive score (CPS) ≥10 tumors, and OS and PFS (RECIST v1.1 by investigator) in ESCC, PD-L1 CPS ≥10, and all pts. Treatment continued until progression, unacceptable toxicity, or withdrawal, or 2 yr. Randomization was stratified by Asia vs Rest of World, adenocarcinoma vs ESCC, and ECOG PS 0 vs 1. MethodsĮligible pts were randomized 1:1 to pembro 200 mg or placebo Q3W for up to 2 yr + chemo (cisplatin 80 mg/m2 Q3W + 5-FU 800 mg/m2 on d1-5 Q3W). KEYNOTE-590 (NCT03189719) is a randomized, international, double-blind study of 1L pembrolizumab (pembro) + chemotherapy (chemo) vs chemo alone in patients (pts) with locally advanced/unresectable or metastatic adenocarcinoma or esophageal squamous cell carcinoma (ESCC) or Siewert type 1 esophagogastric junction adenocarcinoma (EGJ). 18 Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, 100142 - Beijing/CN.17 Medical Oncology, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 07033 - Kenilworth/US.16 Hematology-oncology, Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, 20249 - Hamburg/DE.15 Medical Oncology, Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES. 14 Medicine, Prince of Songkla University Hospital, 90110 - Songkhla/TH.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |